167 related articles for article (PubMed ID: 23596247)
1. Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R;
J Clin Microbiol; 2013 Jul; 51(7):2063-71. PubMed ID: 23596247
[TBL] [Abstract][Full Text] [Related]
2. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
3. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
4. Issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the Maraviroc Switch collaborative study.
Berg J; Paar C; Stoiber H; Klimkait T
J Clin Microbiol; 2013 Dec; 51(12):4285-6. PubMed ID: 24243994
[No Abstract] [Full Text] [Related]
5. Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study".
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R;
J Clin Microbiol; 2013 Dec; 51(12):4287. PubMed ID: 24243995
[No Abstract] [Full Text] [Related]
6. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
[TBL] [Abstract][Full Text] [Related]
8. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
Poveda E; Hernández-Quero J; Pérez-Elías MJ; Ribas MA; Martínez-Madrid OJ; Flores J; Navarro J; Gutiérrez F; García-Deltoro M; Imaz A; Ocampo A; Artero A; Blanco F; Bernal E; Pasquau J; Mínguez-Gallego C; Pérez N; Aiestaran A; García F; Paredes R;
HIV Med; 2017 Aug; 18(7):482-489. PubMed ID: 28035758
[TBL] [Abstract][Full Text] [Related]
9. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
[TBL] [Abstract][Full Text] [Related]
10. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
Gupta S; Neogi U; Srinivasa H; Shet A
J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
[TBL] [Abstract][Full Text] [Related]
11. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.
Symons J; Vandekerckhove L; Paredes R; Verhofstede C; Bellido R; Demecheleer E; van Ham PM; van Lelyveld SF; Stam AJ; van Versendaal D; Nijhuis M; Wensing AM
Clin Microbiol Infect; 2012 Jun; 18(6):606-12. PubMed ID: 21906210
[TBL] [Abstract][Full Text] [Related]
12. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group.
Svicher V; Alteri C; Montano M; Nori A; D'Arrigo R; Andreoni M; Angarano G; Antinori A; Antonelli G; Allice T; Bagnarelli P; Baldanti F; Bertoli A; Borderi M; Boeri E; Bon I; Bruzzone B; Barresi R; Calderisi S; Callegaro AP; Capobianchi MR; Gargiulo F; Castelli F; Cauda R; Ceccherini-Silberstein F; Clementi M; Chirianni A; Colafigli M; D'Arminio Monforte A; De Luca A; Di Biagio A; Di Nicuolo G; Di Perri G; Di Santo F; Fadda G; Galli M; Gennari W; Ghisetti V; Costantini A; Gori A; Gulminetti R; Leoncini F; Maffongelli G; Maggiolo F; Maserati R; Mazzotta F; Meini G; Micheli V; Monno L; Mussini C; Nozza S; Paolucci S; Palù G; Parisi S; Parruti G; Pignataro AR; Quirino T; Re MC; Rizzardini G; Sanguinetti M; Santangelo R; Scaggiante R; Sterrantino G; Turriziani O; Vatteroni ML; Viscoli C; Vullo V; Zazzi M; Lazzarin A; Perno CF
Infection; 2014 Feb; 42(1):61-71. PubMed ID: 24146352
[TBL] [Abstract][Full Text] [Related]
13. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Vandekerckhove L; Verhofstede C; Demecheleer E; De Wit S; Florence E; Fransen K; Moutschen M; Mostmans W; Kabeya K; Mackie N; Plum J; Vaira D; Van Baelen K; Vandenbroucke I; Van Eygen V; Van Marck H; Vogelaers D; Geretti AM; Stuyver LJ
J Antimicrob Chemother; 2011 Feb; 66(2):265-72. PubMed ID: 21196489
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.
Ferrer P; Montecinos L; Tello M; Tordecilla R; Rodríguez C; Ferrés M; Pérez CM; Beltrán C; Guzmán MA; Afani A
Virol J; 2013 Oct; 10():318. PubMed ID: 24165156
[TBL] [Abstract][Full Text] [Related]
16. Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.
Hernández-Novoa B; Madrid-Elena N; Dronda F; Pérez-Elias MJ; Casado JL; Pérez-Molina JA; Moreno A; Estébanez M; González J; Zamora J; Moreno S
J Antimicrob Chemother; 2014 Jul; 69(7):1916-9. PubMed ID: 24623833
[TBL] [Abstract][Full Text] [Related]
17. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
[TBL] [Abstract][Full Text] [Related]
18. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Verhofstede C; Brudney D; Reynaerts J; Vaira D; Fransen K; De Bel A; Seguin-Devaux C; De Wit S; Vandekerckhove L; Geretti AM
HIV Med; 2011 Oct; 12(9):544-52. PubMed ID: 21518222
[TBL] [Abstract][Full Text] [Related]
19. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
